Every Form 4 that Phibro Animal (PAHC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PAHC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PAHC filings page.
Rodriguez Patrick reported acquisition or exercise transactions in this Form 4 filing.
Phibro Animal Health Corp reported that Patrick Rodriguez, VP Finance and Treasurer, received a grant of 1,503 restricted stock units (RSUs) representing Class A Common Stock. The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to his continued employment, and his reported direct holdings after the award are 1,503 shares.
David Glenn reported acquisition or exercise transactions in this Form 4 filing.
PHIBRO ANIMAL HEALTH CORP reported that Chief Financial Officer David Glenn received an award of 3,334 shares of Class A Common Stock in the form of restricted stock units. The award was recorded at a per-share price of $0.00 as a grant, not a market purchase.
The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, contingent on his continued employment through each vesting date. Following this award, Glenn’s directly held Class A Common Stock position is reported as 54,811 shares.
Miller Larry Lee reported acquisition or exercise transactions in this Form 4 filing.
Phibro Animal Health Corp reported that Chief Operating Officer Larry Lee Miller received a grant of 3,522 restricted stock units (RSUs) representing Class A Common Stock on August 6, 2026. These RSUs vest in three substantially equal installments on the first three anniversaries of August 1, 2026, contingent on his continued employment. Following this award, Miller directly holds 38,071 shares of Class A Common Stock, including the RSUs.
BENDHEIM Jonathan reported acquisition or exercise transactions in this Form 4 filing.
PHIBRO ANIMAL HEALTH CORP reported that director Jonathan Bendheim received a grant of 2,716 restricted stock units (RSUs), each representing a contingent right to receive one share of Class A Common Stock. Following this award, his directly held Class A Common Stock position is 5,984 shares.
The RSUs are scheduled to vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to his continued employment through each applicable vesting date.
Weinstein Judith reported acquisition or exercise transactions in this Form 4 filing.
Phibro Animal Health Corp reported an equity compensation award to senior vice president and general counsel Judith Weinstein. She received 2,478 restricted stock units, each representing one share of Class A Common Stock, increasing her direct holdings to 5,453 shares. The RSUs vest in substantially equal installments over three years starting on August 1, 2026, conditioned on continued employment through each vesting date.
BENDHEIM JACK reported acquisition or exercise transactions in this Form 4 filing.
Phibro Animal Health Corp reported that Executive Chairman and 10% owner Jack Bendheim received a grant of 12,103 restricted stock units (RSUs), each representing one share of Class A Common Stock. These RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to his continued employment. Following the award, Bendheim directly holds 26,640 Class A shares and is also reported as having shared voting and investment power over 56,152 Class A shares held by BFI Co., LLC, while disclaiming beneficial ownership beyond his pecuniary interest.
Escudero Lisa Ann reported acquisition or exercise transactions in this Form 4 filing.
PHIBRO ANIMAL HEALTH CORP Senior Vice President of Human Resources Lisa Ann Escudero received a grant of 1,547 restricted stock units (RSUs) of Class A Common Stock on 2026-08-06. The RSUs vest in three substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to continued employment. Following this award, Escudero directly holds 3,434 shares (or share-equivalent RSUs) of Class A Common Stock.
PHIBRO ANIMAL HEALTH CORP reported an equity compensation grant to President and CEO Daniel M. Bendheim. He acquired 11,699 restricted stock units (RSUs), each representing a contingent right to receive one share of Class A Common Stock. The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to his continued employment. Following this award, Bendheim directly holds 15,177 shares of Class A Common Stock, including the RSUs.
PHIBRO ANIMAL HEALTH CORP Executive Chairman and 10% owner Jack Bendheim reported the disposition of 2,303 shares of Class A Common Stock on August 4, 2026. According to the disclosure, these shares were sold in a broker assisted cashless exercise program to satisfy tax withholding obligations upon the vesting and settlement of restricted stock units. Following this transaction, Bendheim directly holds 14,537 Class A shares, and an affiliated entity, BFI Co., LLC, holds 56,152 shares over which he exercises voting and dispositive power while disclaiming beneficial ownership except for his pecuniary interest.
Phibro Animal Health Corp officer Lisa Ann Escudero, Senior Vice President of Human Resources, had 265 shares of Class A Common Stock disposed of on August 4, 2026, at $36.599 per share in a broker-assisted cashless transaction to satisfy tax withholding on vested RSUs, leaving 1,887 shares held directly.
Phibro Animal Health Chief Operating Officer Larry Lee Miller reported a disposition of 635 shares of Class A Common Stock on August 4, 2026. The shares were sold at $36.599 per share in a broker-assisted cashless exercise to satisfy tax withholding obligations related to restricted stock unit vesting. Following the transaction, he directly held 34,549 shares.
PHIBRO ANIMAL HEALTH CORP executive Judith Weinstein reported an other disposition of 472 shares of Class A Common Stock on August 4, 2026, at $36.599 per share. According to the filing, these shares were sold in a broker-assisted cashless exercise to satisfy tax withholding obligations upon vesting and settlement of restricted stock units. Following this transaction, Weinstein directly held 2,975 shares of Class A Common Stock. The transaction was not reported as occurring under a Rule 10b5-1 trading plan.
Phibro Animal Health’s Chief Financial Officer David Glenn reported an other disposition of 840 shares of Class A Common Stock on 2026-08-04 at an average price of $36.599 per share. These shares were sold in a broker-assisted cashless exercise to satisfy tax withholding upon vesting of restricted stock units, leaving him with 51,477 shares directly owned.
Daniel M Bendheim, President and CEO of Phibro Animal Health, reported the sale of 486 shares of Class A Common Stock at $36.599 per share on 2026-08-04. The disclosure states that these shares were sold in a broker-assisted cashless transaction to satisfy tax withholding upon the receipt of shares from vesting of restricted stock units, leaving him with 3,478 shares held directly afterward.
Bendheim Daniel M reported acquisition or exercise transactions in this Form 4 filing.
PHIBRO ANIMAL HEALTH CORP reported that President and CEO Daniel M. Bendheim received a grant of 300,000 Performance Stock Units. Each unit represents a contingent right to one share of Class A Common Stock.
The performance stock units will vest, or be forfeited in full or in part, on June 30, 2031. Vesting depends on achieving specified stock price performance measured as of that date and on Bendheim’s continued employment through that time.
PHIBRO ANIMAL HEALTH CORP director E. Thomas Corcoran bought 10,000 shares of Class A Common Stock in an open-market purchase. The weighted average price was $31.77 per share, with trade prices ranging from $31.66 to $31.85.
After this transaction, he directly holds 41,459 shares, which includes 1,459 shares acquired through a dividend reinvestment plan sponsored by his broker.
Phibro Animal Health insider-related entity BFI Co., LLC sold a net 18,608 shares of Class A Common Stock in open-market transactions from May 5–7, 2026, at weighted average prices ranging from about $47 to $58 per share.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted by BFI on December 11, 2025. BFI now holds 56,152 shares indirectly associated with President and CEO Jack Bendheim, who also directly holds 16,840 shares and disclaims beneficial ownership of BFI’s holdings beyond his pecuniary interest.
Phibro Animal Health Corp reported that BFI Co., LLC, an entity associated with President and CEO Jack Bendheim, sold a total of 21,120 shares of Class A Common Stock in open-market transactions on April 28–30, 2026. The weighted average sale prices ranged from about $52.65 to $56.69 per share, with all sales executed under a Rule 10b5-1 trading plan adopted by BFI on December 11, 2025. Following these sales, BFI’s reported indirect holdings were 74,760 shares, and Bendheim also directly held 16,840 shares. Bendheim may be deemed to share voting and investment power over BFI’s holdings but disclaims beneficial ownership beyond his pecuniary interest.
Phibro Animal Health reported that BFI Co., LLC, an entity associated with President and CEO Jack Bendheim, sold a total of 21,120 shares of Class A Common Stock in open‑market transactions at weighted average prices around $54–$56 per share. These sales were executed under a Rule 10b5-1 trading plan adopted by BFI Co., LLC on December 11, 2025. After the sales, BFI Co., LLC held 95,880 Class A shares, while Jack Bendheim directly held 16,840 Class A shares.
Phibro Animal Health Corp’s CEO-linked entity BFI Co., LLC converted 100,000 shares of Class B Common Stock into 100,000 shares of Class A Common Stock and then sold 21,120 Class A shares in open-market transactions from April 14–16 under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. Reported weighted average sale prices ranged from about $53.80 to $59.83. After these trades, BFI held 117,000 Class A shares indirectly, while Jack Bendheim also directly held 16,840 Class A shares, showing that a substantial position remains after these planned sales.
Phibro Animal Health (PAHC) insider activity centers on BFI Co., LLC, an entity associated with President and CEO Jack Bendheim. BFI Co., LLC reported open-market sales totaling 14,080 shares of Class A Common Stock on March 30 and March 31 under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. Reported weighted average sale prices were about $53.54 and $54.31 per share on March 30 and about $53.87 and $54.35 per share on March 31. After these transactions, BFI Co., LLC holds 38,120 shares indirectly, while Bendheim directly holds 16,840 shares. Bendheim may be deemed to share voting and investment power over BFI’s holdings but disclaims beneficial ownership beyond his pecuniary interest.
Phibro Animal Health Corp reported that BFI Co., LLC, an entity over which President and CEO Jack Bendheim exercises voting and dispositive power, sold a total of 21,120 shares of Class A Common Stock in open-market transactions on March 24–26, 2026.
The weighted average sale prices ranged from about $52.8772 to $57.1702 per share. Following these indirect sales, BFI Co., LLC held 52,200 Class A shares, while Bendheim directly held 16,840 shares. The sales were executed under a Rule 10b5-1 trading plan adopted on December 11, 2025, indicating they were pre-scheduled rather than discretionary.
Phibro Animal Health insider activity shows an entity associated with President and CEO Jack Bendheim selling Class A Common Stock. BFI Co., LLC sold a total of 22,880 shares in open-market transactions on March 17–19 at reported weighted average prices between $51.6590 and $53.6436 per share, under a Rule 10b5-1 trading plan adopted on December 11, 2025. Following these sales, BFI Co., LLC held 73,320 shares indirectly, while Jack Bendheim also directly held 16,840 shares. Bendheim may be deemed to share voting and investment power over BFI’s holdings but disclaims beneficial ownership except for his pecuniary interest.
Phibro Animal Health insider activity shows entity BFI Co., LLC, which is associated with President and CEO Jack Bendheim, converting and selling shares. BFI converted 100,000 shares of Class B Common Stock into the same number of Class A shares and then sold 5,280 Class A shares at a weighted average price of $48.91 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025, indicating it was scheduled in advance. Following these transactions, BFI held 96,200 Class A shares indirectly, while Bendheim directly held 16,840 Class A shares, and BFI continued to hold 19,596,034 Class B shares, which remain convertible into Class A on a one-for-one basis.
Phibro Animal Health CorpBFI Co., LLC, an entity associated with President and CEO Jack Bendheim, sold a total of 21,120 shares of Class A common stock in open-market transactions from February 24–26, 2026, under a pre-established Rule 10b5-1 trading plan adopted on May 30, 2025.
The reported weighted-average sale prices for these trades were around $51–$54 per share, and the filing notes that some shares are held directly by Jack Bendheim while others are held indirectly through BFI Co., LLC.
BFI Co., LLC, an entity associated with Phibro Animal Health’s President and CEO Jack Bendheim, reported pre-planned open-market sales of 14,080 shares of Class A Common Stock under a Rule 10b5-1 trading plan. The weighted average sale prices were $50.2568, $51.3830 and $51.9644 per share.
After these indirect sales, BFI Co., LLC reported holding 22,600 shares, while Jack Bendheim directly held 16,840 shares. Bendheim may be deemed to share voting and investment power over BFI’s holdings but disclaims beneficial ownership beyond his pecuniary interest.
Phibro Animal Health reported insider transactions involving an entity associated with its President and CEO, Jack Bendheim. BFI Co., LLC, a ten percent owner, sold a total of 14,080 shares of Class A Common Stock in open-market transactions on February 13 and 18, 2026 under a pre-established Rule 10b5-1 trading plan adopted on May 30, 2025. The weighted average sale prices were around $51–$52 per share, with detailed price ranges disclosed in the footnotes. After these sales, BFI held 36,680 shares, and Bendheim also directly held 16,840 shares. The filing notes that Bendheim may be deemed to share voting and investment power over BFI’s holdings but disclaims beneficial ownership except to the extent of his pecuniary interest.
Phibro Animal Health insider activity shows that BFI Co., LLC, an entity associated with President and CEO Jack Bendheim, sold a total of 72,198 shares of Class A common stock in open-market transactions on February 10–11, 2026. The shares were sold under a pre-established Rule 10b5-1 trading plan adopted by BFI on May 30, 2025, at weighted average prices ranging from about $51.61 to $52.21. Following these indirect sales, BFI continued to hold 50,760 shares, while Bendheim directly held 16,840 shares.
David Glenn reported acquisition or exercise transactions in a Form 4 filing for PAHC. The filing lists transactions totaling 72,528 shares at a weighted average price of $51.63 per share. Following the reported transactions, holdings were 240,000 shares.
Phibro Animal Health Corp’s insider filing shows activity on February 5, 2026 involving an entity associated with President and CEO Jack Bendheim. BFI Co., LLC converted 185,000 shares of Class B Common Stock into 185,000 shares of Class A Common Stock at an exercise price of $0.
BFI then executed several open-market sales of Class A shares under a Rule 10b5-1 trading plan, with individual trades ranging from 409 to 46,275 shares at weighted average prices between $44.4688 and $49.5718. After these transactions, BFI indirectly held 122,958 Class A shares, while Jack Bendheim directly held 16,840 Class A shares.
Phibro Animal Health insider activity shows trades by BFI Co., LLC, an entity associated with President and CEO Jack Bendheim and a 10% owner. On February 4, 2026, BFI converted 30,000 shares of Class B Common Stock into Class A on a one-for-one basis at $0 per share.
BFI then sold Class A shares in several transactions: 6,689 shares at $41.2508, 2,971 shares at $41.9667, and 3,520 shares at $41.1544, all reported as weighted average prices under a Rule 10b5-1 trading plan adopted on May 30, 2025. After these trades, BFI held 48,800 Class A shares indirectly, while Bendheim directly held 16,840 Class A shares and BFI continued to hold additional Class B shares. Bendheim may be deemed to share voting and investment power over BFI’s holdings but disclaims beneficial ownership except for his pecuniary interest.
Phibro Animal Health (PAHC) insider activity centers on planned sales by BFI Co., LLC, an entity associated with President and CEO Jack Bendheim. BFI sold 6,772 Class A Common shares at a weighted average price of $40.1192 on January 29, 2026, and 6,693 shares at $40.0941 on January 30, 2026, under a Rule 10b5-1 trading plan adopted on May 30, 2025. After these transactions, BFI held 38,673 and then 31,980 shares indirectly, while Bendheim also directly held 16,840 Class A Common shares.
Phibro Animal Health insider activity shows trades by major shareholder BFI Co., LLC, an entity over which President and CEO Jack Bendheim has voting and dispositive power. On January 23, 2026, BFI sold 1,235 shares of Class A Common Stock at a weighted average price of $40.5538 per share under a Rule 10b5-1 trading plan adopted on May 30, 2025. On January 26, 2026, BFI converted 30,000 shares of Class B Common Stock into Class A Common Stock on a one-for-one basis at an exercise price of $0. Following these transactions, BFI indirectly held 45,445 Class A shares, while Jack Bendheim also directly held 16,840 Class A shares.
Phibro Animal Health’s 10% owner BFI Co., LLC, an entity associated with President and CEO Jack Bendheim, reported planned sales of Class A common stock under a Rule 10b5-1 trading plan adopted on May 30, 2025. On January 21, 2026, BFI sold 14,687 shares at a weighted average price of $41.6782 per share. On January 22, 2026, it sold 11,875 shares at a weighted average price of $41.9086 and 1,283 shares at a weighted average price of $42.6774, with each price reflecting multiple trades within stated ranges. The filing also shows that Jack Bendheim directly held 16,840 Class A shares as of January 21, 2026.
Phibro Animal Health Corporation insider activity centers on BFI Co., LLC, an entity associated with President and CEO Jack Bendheim. On January 13, 2026, BFI sold 7,551 shares of Class A common stock at a weighted average price of $40.3154 under a Rule 10b5-1 trading plan. On January 14, 2026, BFI converted 20,000 shares of Class B common stock into 20,000 shares of Class A at a conversion price of $0, then sold 3,258 shares at a weighted average price of $40.4592 and 393 shares at $41.1375. On January 15, 2026, BFI sold an additional 2,932 shares at a weighted average price of $40.0233. Following these transactions, BFI indirectly holds 44,525 shares of Class A common stock and 19,941,034 shares of Class B common stock, while Jack Bendheim directly holds 16,840 shares of Class A common stock.
Phibro Animal Health Corporation insider activity centers on an entity linked to its President and CEO, Jack Bendheim. On 01/09/2026, BFI Co., LLC sold 213 shares of Phibro’s Class A common stock at $40.16 per share under a pre-arranged Rule 10b5-1 trading plan adopted on May 30, 2025. Following this sale, BFI held 38,659 Class A shares, over which Bendheim exercises voting and dispositive power and may be deemed to share voting and investment power, while disclaiming beneficial ownership beyond his pecuniary interest. Separately, Bendheim directly held 16,840 Class A shares after the reported transactions.
Phibro Animal Health Corporation insider activity centered on an entity linked to its President and CEO, Jack Bendheim. On January 7, 2026, BFI Co., LLC, a 10% owner, sold 328 shares of Phibro’s Class A Common Stock at a weighted average price of $40.0877 per share under a pre-arranged Rule 10b5-1 trading plan adopted on May 30, 2025. Following this sale, BFI held 38,872 shares indirectly reported, over which Bendheim exercises voting and dispositive power and may be deemed to share voting and investment power through BFI.
Separately, Jack Bendheim directly held 16,840 shares of Class A Common Stock after the reported transactions. The price range for the sold shares was from $40.035 to $40.26, with the reported price reflecting the weighted average across multiple trades.
Phibro Animal Health Corp. insider Jack Bendheim, who serves as President, CEO, director and a 10% owner, reported sales of Class A common stock on 12/11/2025.
The transactions, made by affiliated entity BFI Co., LLC under a Rule 10b5-1 trading plan adopted on 05/30/2025, totaled 2,757 shares at a weighted average price of $40.6096 and 2,995 shares at a weighted average price of $41.2167, executed in multiple trades within stated price ranges. After these sales, BFI is shown as indirectly holding 39,200 shares, while Bendheim directly holds 16,840 shares.
Phibro Animal Health (PAHC) President and CEO Jack Bendheim, who is also a director and 10% owner, reported sales of Class A common stock on 11/20/2025. Through BFI Co., LLC, he sold 3,459 shares at a weighted average price of $41.752 and an additional 61 shares at $42.32, all under a pre-arranged Rule 10b5-1 trading plan adopted on May 30, 2025.
Following these transactions, 46,221 shares were reported as indirectly owned before the second sale and 46,160 shares as indirectly owned afterward through BFI, with another 16,840 shares held directly by Bendheim. The filing notes that the reported prices reflect weighted averages across multiple trades between $41.29 and $42.25, and Bendheim disclaims beneficial ownership of BFI-held shares beyond his economic interest.
Phibro Animal Health (PAHC) president and CEO Jack Bendheim, a director and 10% owner, reported insider transactions involving the company’s Class A and Class B common stock. On 11/14/2025, 55,000 shares of Class B common stock were converted into 55,000 shares of Class A common stock at an exercise price of $0 under a derivative security.
Following the conversion, indirect holdings sold 5,280 Class A shares on 11/17/2025 at a weighted average price of $44.5557 and 5,260 shares plus 20 shares on 11/18/2025 at weighted average prices of $43.8196 and $44.28, respectively, under a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025. After these transactions, 49,680 Class A shares were held indirectly through BFI and 16,840 Class A shares were held directly, with 19,991,034 Class B derivative securities indirectly owned.
Phibro Animal Health (PAHC) insider activity: A Form 4 reports transactions by Jack Bendheim and BFI Co., LLC. On 11/11/2025, 15,000 shares of Class B Common Stock were converted into Class A Common Stock at $0. On 11/12/2025, 21,536 Class A shares were sold at a weighted average price of $45.2255. On 11/13/2025, additional sales included 7,147 shares at $44.3689 and 1,654 shares at $44.929. These sales were effected under a Rule 10b5-1 trading plan adopted on May 30, 2025. Following the reported transactions, Class A shares beneficially owned were 5,240 indirect (via BFI) and 16,840 direct.
Phibro Animal Health (PAHC): Reporting persons Jack Bendheim and BFI Co., LLC disclosed open‑market sales of Class A common stock totaling 41,823 shares on 11/07/2025 and 11/10/2025, executed at average prices ranging from $42.8554 to $46.3558 under a Rule 10b5‑1 trading plan adopted on May 30, 2025.
Following these transactions, 20,577 shares are held indirectly via BFI and 16,840 shares are held directly by Mr. Bendheim. Bendheim is a Director, President and CEO, and 10% owner.
Phibro Animal Health (PAHC): Jack Bendheim and BFI Co., LLC reported insider transactions on Form 4. On 11/04/2025, BFI converted 25,000 shares of Class B Common Stock into Class A Common Stock (one-for-one, no expiration). On 11/04/2025 and 11/05/2025, BFI sold a total of 7,040 Class A shares under a Rule 10b5-1 trading plan adopted on May 30, 2025, at weighted average prices ranging from $40.9805 to $43.6205.
Following these transactions, 62,400 Class A shares were indirectly beneficially owned and 16,840 Class A shares were directly beneficially owned. Bendheim is a Director, President and CEO, and 10% Owner, and may be deemed to share voting and investment power over BFI’s holdings.
Phibro Animal Health (PAHC) insider filing shows planned sales by President and CEO Jack Bendheim under a Rule 10b5-1 plan adopted on May 30, 2025. BFI Co., LLC sold 3,520 Class A shares on 10/28/2025 at a weighted average price of $41.5561, 3,520 on 10/29/2025 at $41.6554, and 3,520 on 10/30/2025 at $41.0745. After these transactions, 44,440 shares were beneficially owned indirectly through BFI, and 16,840 shares were held directly.
Phibro Animal Health (PAHC) insider filings show sales of Class A common stock tied to a pre‑set Rule 10b5‑1 plan by BFI Co., LLC, over which CEO and director Jack Bendheim exercises voting and dispositive power. Reported transactions occurred on 10/22/2025 (11,859 shares at a weighted average price of $40.2692), 10/23/2025 (3,520 shares at $40.1796), and 10/24/2025 (3,520 shares at $41.749).
Following these trades, 55,000 shares were beneficially owned indirectly via BFI, and 16,840 shares were held directly. The 10b5‑1 trading plan was adopted on May 30, 2025.
Phibro Animal Health (PAHC) insider activity: Reporting persons BFI Co., LLC and Jack Bendheim (Director, 10% Owner, President and CEO) reported sales and a conversion. Under a Rule 10b5‑1 plan, BFI sold 700 Class A shares on 10/17/2025 at a weighted average price of $40.0319 and 16,075 Class A shares on 10/20/2025 at a weighted average price of $40.3842.
On 10/21/2025, 50,000 shares of Class B Common Stock were converted into 50,000 shares of Class A on a one‑for‑one basis. Following these transactions, 73,899 Class A shares were indirectly beneficially owned, and 16,840 Class A shares were directly owned. After the conversion, 20,086,034 shares of Class B were indirectly beneficially owned.
Insider sales reported for PHIBRO ANIMAL HEALTH CORP (PAHC). On 09/30/2025 the filing shows dispositions of Class A common stock by BFI Co., LLC and Jack Bendheim. BFI reported a sale of 20,664 shares at a weighted average price of $40.38 (individual trade prices ranged $40.00–$40.635) and Jack Bendheim reported a sale of 16,840 shares.
The filing states the BFI sales were effected under a Rule 10b5-1 trading plan adopted May 30, 2025. After the reported transactions, BFI is shown as beneficially owning 40,674 shares, and Jack Bendheim directly holds the 16,840 shares he sold before the disposition shown on this Form 4. The filing is signed by an attorney-in-fact on behalf of both reporting persons.
Jack Bendheim and BFI Co., LLC filed a Form 4 reporting insider transactions in Phibro Animal Health Corporation (PAHC). On 09/18/2025 BFI sold 7,022 shares of Class A common stock at a weighted average price of $40.2637 under a Rule 10b5-1 trading plan adopted May 30, 2025. On 09/19/2025 the reporting parties acquired 30,000 Class A shares via conversion of 30,000 Class B shares at no cash cost. Following the reported transactions, certain Class A holdings are reported as 61,338 shares (indirect) and derivative-related Class A shares underlying converted Class B stock total 30,000. Jack Bendheim is identified as a director, President and CEO, and a >10% owner; BFI is a >10% owner.